-- New Hope Liuhe (SHE:000876) によると、第1四半期に8億9770万元の帰属損失を計上した。これは前年同期の4億4470万元の帰属利益から大幅な悪化となる。
養豚会社である同社は1株当たり0.20元の損失を計上した。前年同期は1株当たり0.90元の利益であった。
営業収益は前年同期比12%増の273億元となり、前年同期の244億元から増加している。
-- New Hope Liuhe (SHE:000876) によると、第1四半期に8億9770万元の帰属損失を計上した。これは前年同期の4億4470万元の帰属利益から大幅な悪化となる。
養豚会社である同社は1株当たり0.20元の損失を計上した。前年同期は1株当たり0.90元の利益であった。
営業収益は前年同期比12%増の273億元となり、前年同期の244億元から増加している。
US President Donald Trump has granted a presidential permit for Bridger Pipeline Expansion, a private Wyoming company and subsidiary of Bridger Pipeline, to construct, connect and operate a pipeline at the border with Canada in Montana for crude oil and refined products, the White House said on Thursday.The pipeline will have a 36-inch diameter and run from the border between the US and Canada to a mainline shutoff valve or pumping station within 2,000 feet of the border, the statement, signed by Trump, said.Conditions applied to the permit include maintaining the facility to a high standard and informing the authorities of any ownership change, among other stipulations.
Imperial Oil's (IMO.TO) net income dropped year over year in the first quarter, the company said Friday.Imperial Oil booked a net income of C$940 million, or $1.94 per share, falling from $1.29 billion, or $2.52 per share, in the year-ago period.Analysts expected Imperial Oil's earnings at $2.30 per share, according to FactSet.Revenue slipped to $12.45 billion from $12.52 billion while expenses increased to $11.21 billion from $10.83 billion.Upstream production stood at 419,000 gross oil-equivalent barrels per day in the first quarter, rising from 418,000 gross oil-equivalent barrels per day in the year-ago period."Against a backdrop of significant volatility in global commodity markets, we remain committed to our long-standing corporate strategy of maximizing the value of our existing assets while progressing advantaged growth opportunities," Chairman, President and Chief Executive Officer John Whelan said.Imperial Oil declared a dividend of $0.87 per share for the second quarter, unchanged from the first quarter. The dividend is payable July 1 to shareholders of record as of June 4.The company plans to renew its normal course issuer bid in June.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Moderna's Q1 2026 revenue tripled to $389M, beating the consensus view by $154M, due to COVID-19 vaccine deliveries under international partnerships. Net loss widened to $(3.40) per share from $(2.52) prior year, though beat consensus by $0.48, primarily due to a $0.9B litigation settlement charge that added $(2.22) to EPS. We view the strong revenue performance and international expansion as positive, with international markets contributing 80% of revenue and completion of the first U.K. partnership shipment. Management maintained the 2026 guidance for up to 10% revenue growth with 50/50 U.S./international split. We believe regulatory milestones including European approval of combination vaccines and pipeline advancement demonstrate execution on its diversification strategy. Key upcoming catalysts include Phase 3 melanoma results, norovirus efficacy data, and the August PDUFA date for seasonal flu vaccine mRNA-1010.